DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA) today announces that it has been invited to present
its late-breaking abstract for a poster and presentation covering results of
pre-clinical studies of DM-204 for the treatment of Type 2 diabetes. The
material will be presented on December 5, 2011 at the 21st biennial World
Diabetes Congress organized by the International Diabetes Federation (IDF) in
Dubai, United Arab Emirates.


The poster and presentation is titled "Novel DM-204 monoclonal antibody triggers
insulin secretion, insulin sensitivity and reduction in blood pressure." The
Company previously released high-level results that animals acutely treated with
DM-204 demonstrated a 291% increase in maximal glucose infusion rate (p greater
than 0.0035) measured in the hyperinsulinemic euglycemic clamp model. In a
separate study, DM-204 lowered systolic blood pressure by 15 mmHg (p less than
0.05).


"We look forward to sharing the exceptional results of our DM-204 Type 2
diabetes program at the IDF World Diabetes Congress that is expected to draw
more than 15,000 participants and is one of the largest and most important
healthcare conferences in the world", stated Dr. Mark Williams, Vice President
of Research at DiaMedica who will be presenting the results of DiaMedica's novel
monoclonal antibody to treat both Type 2 diabetes and one of its major
complications, high blood pressure.


About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic
compounds aimed to improve the lives of patients with diabetes and other major,
medically-unmet diseases. DiaMedica's lead compound, DM-199, represents a novel
approach to treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting the autoimmune
attack on beta cells; 2) proliferating insulin producing beta cells and 3)
improving glucose control.


DiaMedica is also developing DM-204, a monoclonal antibody that inhibits the
enzyme glycogen synthase kinase 3 beta (GSK3B). In preclinical studies, DM-204
significantly improved glucose control and decreased blood pressure. 


The company is listed on the TSX Venture Exchange under the trading symbol 'DMA'. 

Caution Regarding Forward-Looking Information 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024